Strata Critical Medical (SRTA) Gross Margin (2021 - 2026)

Strata Critical Medical has disclosed Gross Margin across 6 years of filings, most recently posting 20.95% for Q1 2026.

• In Q1 2026, Gross Margin rose 133.0% year-over-year to 20.95%; the TTM figure through Mar 2026 stood at 2.66% (up 3039.0% YoY), while the FY2025 annual figure was 20.86%, up 71.0% from the prior year.
• Gross Margin advanced to 20.95% in Q1 2026, from 131.96% in the prior quarter.
• Over the last five years, Gross Margin for SRTA reached as high as 97.69% in Q2 2025 and fell as low as 268.66% in Q4 2023.
• The 5-year median for Gross Margin is 20.82% (2024), against an average of 10.34%.
• Annual changes were most pronounced in 2023 — Gross Margin tumbled 7742 bps — and 2025, when it soared 8738 bps.
• A 5-year view of Gross Margin shows it stood at 14.34% in 2022, then plunged by 1973 bps to 268.66% in 2023, then grew by 18 bps to 219.34% in 2024, then soared by 40 bps to 131.96% in 2025, then surged by 116 bps to 20.95% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 20.95%, 131.96%, and 23.56% for Q1 2026, Q4 2025, and Q3 2025 respectively.